{
  "docId": "019de514-c6ee-70fe-9ed1-115332e66453",
  "docSlug": "7d8148a830366811cd98c46e453c2fa7",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 10 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 10,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-c6ee-70fe-9ed1-115332e66453/7",
  "deckHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453",
  "deckJsonHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453.json",
  "deckAnchorHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.249,
        "w": 0.87,
        "x": 0.08,
        "y": 0.403
      },
      "kind": "diagram",
      "text": "Late Q4 2020, 1H 2021, 2H 2021, Q1 2022, Adintrevimab IND Enabling & Submission, Phase 1 First in Human 1st Subject Dosed, EVADE (prevention) Ph2/3 Enrollment Initiated (US), STAMP (treatment) Ph2/3 Enrollment Initiated (ex-US), Adintrevimab Topline Data",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53928d27-c7f4-4dc7-ac59-071d1b68ce90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.023,
        "w": 0.066,
        "x": 0.889,
        "y": 0.102
      },
      "kind": "image",
      "text": "INVIVYD",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfc4272c-1ba5-42f8-80a2-66047df99c65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.76,
        "x": 0.045,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "Adintrevimab is an investigational product candidate that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d8c335e-dba2-4d8d-9081-f166d4f6db4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.069,
        "w": 0.79,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "DEMONSTRATED DEVELOPMENT SUCCESS WITH ADINTREVIMAB: FROM IND TO TOPLINE DATA IN 16 MONTHS",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "997a5fbf-6dc6-4061-85d7-02971c05f963",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "8f586047-fdbe-4793-9641-0c1f5c37eadc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation of Invivyd's combination approach and pipeline of antibodies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ebd5e9d0-7739-45d1-9c72-3cc4af38795c",
      "evidence": "The presentation of Invivyd's combination approach and pipeline of antibodies",
      "position": 1,
      "objective": "Why is Invivyd's approach effective in developing COVID-19 product candidates?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}